According to the results of a single-center, prospective, crossover study, darbepoetin alfa—a hyperglycosylated, and therefore longer-acting, derivative of epoetin—is a more effective ...

Purpose: The effectiveness of every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia was evaluated. Methods: Women receiving chemotherapy for ...

We did not control for this potential confounder, since our focus was on hospitalwide use of darbepoetin and epoetin, regardless of the clinical outcomes directly related to their use. Another ...

This leaflet answers some common questions about Aranesp (darbepoetin alfa). It does not contain all the available information. It does not take the place of talking to your doctor, nurse or ...

Darbepoetin alfa 10mcg/0.4mL, 25mcg/0.42mL, 40mcg/0.4mL, 60mcg/0.3mL, 100mcg/0.5mL, 150mcg/0.3mL, 200mcg/0.4mL, 300mcg/0.6mL, 500mcg/mL; per prefilled syringe; for IV ...

MBV already has a candidate drug in phase 1, MK2578 (pegylated erythropoietin), designed to compete with Thousand Oaks, California–based Amgen's Aranesp (darbepoetin alfa), and at least five ...